Albertsons Might Suffer from Slower Pharmacy Sales Despite Strong Weight-Loss Drug Demand -- Market Talk
Dow Jones
Apr 12, 2025
1252 ET - Albertsons will likely post decent results next week amid a bumpy macro backdrop, UBS analysts say in a research note. The grocery store chain's exposure to tariffs is likely modest, but still important for earnings, the analysts say. UBS also thinks Albertsons' top line performance could have been hit by slower pharmacy industry sales, even if demand for weight-loss drugs remained very strong. "While it's likely making good progress on its strategic initiatives, we expect for it to strike a cautious tone on the call, especially when considering how tariff uncertainty could impact broader consumer behavior," the analysts add. Albertsons slips 0.8%.(sabela.ojea@wsj.com; @sabelaojeaguix)
(END) Dow Jones Newswires
April 11, 2025 12:52 ET (16:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.